Allogene Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Allogene Therapeutics filed a Form 8-K under Item 8.01 on June 1, 2020, reporting a public offering of common stock. The offering closed on June 4, 2020. The filing does not provide operating results for a quarterly or annual reporting period.
Key financial metrics and capital structure
- Shares offered: 11,702,128 shares of common stock initially, plus 1,755,319 additional shares under the underwriters’ option.
- Option exercise: The underwriters exercised the option in full, resulting in total shares sold of 13,457,447.
- Public offering price: $47.00 per share.
- Gross proceeds: Approximately $632.5 million, before underwriting discounts, commissions, and offering expenses.
- Net proceeds: Not provided in the filing text.
- Revenue, profit, cash flow, margins, debt, and liquidity: The filing does not provide clear values for these metrics.
Material changes versus the prior comparable period
The filing reports a material capital-raising transaction but does not present comparative financial statements or quantify changes in operating performance versus a prior period. The offering increased the company’s common stock outstanding, although the filing text does not provide the pre-offering share count or resulting ownership dilution.
Guidance, outlook, risks, contingencies, and unusual items
- No financial guidance or operating outlook is provided.
- The underwriting agreement includes customary representations, warranties, closing conditions, indemnification obligations, and termination provisions.
- Underwriting discounts, commissions, and offering expenses reduce the gross proceeds; their amounts are not provided in the filing text.
- The offering was conducted under the company’s effective Form S-3 registration statement and related prospectus supplement.
Important facts for investors to verify
- Confirm the net proceeds after underwriting discounts, commissions, and offering expenses.
- Review the filed underwriting agreement for transaction conditions, indemnification provisions, and termination rights.
- Assess the effect of issuing 13,457,447 shares on dilution and shares outstanding.
- Review subsequent filings for the company’s use of proceeds, updated liquidity, and any related financing or operating developments.